Human il-17f and other il-17f-related proteins and methods related thereto

Abstract

Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpesvirus herpes CTLA-8 proteins are also provided.

1 - 27 . (canceled) 
     
     
         28 . A method of stimulating hematopoiesis in a subject, the method comprising administering to the subject a therapeutically effective amount of a composition comprising an amino acid sequence selected from the group consisting of:
 (a) the amino acid sequence of SEQ ID NO:2;   (b) the amino acid sequence of SEQ ID NO:2 from amino acids 11 to 163;   (c) the amino acid sequence of SEQ ID NO:2 from amino acids 29 to 163;   (d) the amino acid sequence of SEQ ID NO:2 from amino acids 31 to 163; and   (e) fragments of (a), (b), (c) or (d) having CTLA-8 activity.   
     
     
         29 . The method of  claim 28 , wherein said subject is treated to produce an effect selected from the group consisting of proliferation of myeloid cells or progenitors, proliferation of erythroid cells or progenitors, proliferation of lymphoid cells or progenitors, induction of IL-3 production and induction of GM-CSF production. 
     
     
         30 . The method of  claim 33 , wherein the myeloid cells are neutrophils. 
     
     
         31 . A method of inhibiting angiogenesis in a subject, the method comprising administering to the subject a therapeutically effective amount of a composition comprising an amino acid sequence selected from the group consisting of:
 (a) the amino acid sequence of SEQ ID NO:2;   (b) the amino acid sequence of SEQ ID NO:2 from amino acids 11 to 163;   (c) the amino acid sequence of SEQ ID NO:2 from amino acids 29 to 163;   (d) the amino acid sequence of SEQ ID NO:2 from amino acids 31 to 163; and   (e) fragments of (a), (b), (c) or (d) having CTLA-8 activity.   
     
     
         32 . The method of  claim 31 , wherein the subject is treated to prevent growth or proliferation of vascular endothelial cells, tumor growth, or angiogenesis-dependent tissue growth. 
     
     
         33 . The method of  claim 29 , wherein the effect is proliferation of myeloid cells.